IPO
Ergomed plc, a company focused on providing specialised services to the global pharmaceutical industry, announces its unaudited interim results for the six months ended 30 June 2019.
Tacalyx announced that it has successfully secured €7 million in seed funding.
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the central nervous system (CNS), provides a business update for the last twelve months.
Polarean Imaging plc, the medical-imaging technology company, with a proprietary drug-device combination product for the magnetic resonance imaging (MRI) market, announces its unaudited interim results for the six months ended 30 June 2019.
Catalyst Pharmaceuticals, Inc., is commenting on trading activity in its common stock and on the current state of its capital resources.
Faron announces its unaudited interim results for the six months ended 30 June 2019.
Using a combination of machine learning and parallel chemistry to change the way we think about treating disease
CARB-X is awarding Procarta Biosystems, a UK-based biotech company, up to US$2.2 million in non-dilutive funding with the possibility of $7.0 million more if certain project milestones are met, to develop a new class of antibiotics to treat Gram-negative ESKAPE pathogens.
CMR Surgical Limited announces that it has raised £195 million ($240 million) to fully fund the global commercialisation of the business.
Race Oncology Limited is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has joined the Board of Directors of Race Oncology Ltd.
PRESS RELEASES